Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Janus Kinase Inhibitors Promising for Difficult-to-Treat RA

  |  

Also at one year, no specific patient background factors predicting jakinib continuation were found. These results show that—although this was a small number of retrospectively evaluated patients—patients with difficult-to-treat RA may be effectively treated with the jakinibs baricitinib and tofacitinib, regardless of background demographics or disease parameters. The authors note that switching between jakinibs and the use of other jakinibs require further investigation.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Kamiya M, Togawa D, Mori S, et al. Efficacy of janus kinase inhibitors for difficult-to-treat RA in clinical practice [abstract POS0088]. Ann Rheum Dis. 2021 Jun;80(suppl 1):252–253.
  2. Nagy G,  Roodenrijs NMT, WEsing PMJ, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jun;80(1):31–35.

Related Articles

    Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

    Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

    Janus kinase 1 protein.

    Researchers Give Update on Janus Kinase (JAK) Inhibitors

    SNOWMASS VILLAGE, COLO.—Janus kinase inhibitors—or Jakinibs—are a relatively new class of disease-modifying anti-rheumatic drugs (DMARDs) that perform well and have a safety profile comparable to biologics. This group of drugs was the subject of The New Frontier: Comparative Safety of JAK Inhibitors, a presentation given at the ACR Winter Symposium by Kevin L. Winthrop, MD,…

    The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

    ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…